The role of pyroptosis-related lncRNA risk signature in ovarian cancer prognosis and immune system

被引:2
作者
Wu, Yanling [1 ]
Liang, Lei [1 ]
Li, Qin [2 ]
Shu, Lilu [2 ]
Wang, Peter [2 ]
Huang, Shufeng [1 ]
机构
[1] Shenzhen Qianhai Shekou Free Trade Zone Hosp, Dept Gynecol, Shenzhen 518067, Guangdong, Peoples R China
[2] Zhejiang Zhongwei Med Res Ctr, Dept Res & Dev, Hangzhou 310018, Zhejiang, Peoples R China
关键词
LncRNA; Ovarian cancer; Target; Pyroptosis; Immune system; CELL-DEATH;
D O I
10.1007/s12672-023-00767-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ovarian cancer is a leading cause of death in females with gynecologic cancers. Pyroptosis is a relatively new discovered programmed cell death that is believed to be associated with inflammation. However, studies on pyroptosis-related lncRNAs in ovarian cancer are limited. In this study, we identified 29 pyroptosis-related genes and screened out 72 pyroptosis-related lncRNAs. Furthermore, the 72 lncRNAs were eliminated to 2 survival-related lncRNAs using Cox regression and Lasso regression to build an ovarian cancer prognostic prediction signature and were further validated on the test set. We adopted a riskscore from the two-gene signature, and the survival in low-risk group was higher than the high-risk group. Functional enrichment analysis indicated that the differentially expressed genes (DEGs) between two risk groups were associated with tumor immunity. This study implies that pyroptosis-related genes are closely related to tumor immunity and could be potential therapeutic factors for ovarian cancer treatment.
引用
收藏
页数:14
相关论文
共 60 条
  • [1] LNCAROD promotes the proliferation and migration of gastric cancer: a bioinformatics analysis and experimental validation
    Ansari, Sara
    Nikpour, Parvaneh
    [J]. FUNCTIONAL & INTEGRATIVE GENOMICS, 2023, 23 (01)
  • [2] LNCAROD is stabilized by m6A methylation and promotes cancer progression via forming a ternary complex with HSPA1A and YBX1 in head and neck squamous cell carcinoma
    Ban, Yuanyuan
    Tan, Pingqing
    Cai, Jing
    Li, Junjun
    Hu, Meng
    Zhou, Ying
    Mei, Yan
    Tan, Yixin
    Li, Xiaoling
    Zeng, Zhaoyang
    Xiong, Wei
    Li, Guiyuan
    Li, Xiayu
    Yi, Mei
    Xiang, Bo
    [J]. MOLECULAR ONCOLOGY, 2020, 14 (06) : 1282 - 1296
  • [3] Pyroptosis: host cell death and inflammation
    Bergsbaken, Tessa
    Fink, Susan L.
    Cookson, Brad T.
    [J]. NATURE REVIEWS MICROBIOLOGY, 2009, 7 (02) : 99 - 109
  • [4] Differential Expression and Copy Number Variation of Gasdermin (GSDM) Family Members, Pore-Forming Proteins in Pyroptosis, in Normal and Malignant Serous Ovarian Tissue
    Berkel, Caglar
    Cacan, Ercan
    [J]. INFLAMMATION, 2021, 44 (06) : 2203 - 2216
  • [5] CACNA1C-AS2 inhibits cell proliferation and suppresses cell migration and invasion via targeting FBXO45 and PI3K/AKT/mTOR pathways in glioma
    Cao, Tong
    Cui, Yue
    Wang, Yingying
    Wu, Linhui
    Yu, Ke
    Chen, Kai
    Xia, Jun
    Li, Yuyun
    Wang, Zhiwei Peter
    Ma, Jia
    [J]. APOPTOSIS, 2022, 27 (11-12) : 979 - 991
  • [6] Derivation, Comprehensive Analysis, and Assay Validation of a Pyroptosis-Related lncRNA Prognostic Signature in Patients With Ovarian Cancer
    Cao, Xueyan
    Zhang, Qingquan
    Zhu, Yu
    Huo, Xiaoqing
    Bao, Junze
    Su, Min
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [7] Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1/PD-L1
    Chardin, Laure
    Leary, Alexandra
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [8] LINC01094 promotes the invasion of ovarian cancer cells and regulates the Wnt/β-catenin signaling pathway by targeting miR-532-3p
    Chen, Haiyan
    Liu, Yanlin
    Liu, Ping
    Dai, Qiuxiang
    Wang, Peiliang
    [J]. EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2021, 22 (05)
  • [9] Long Intergenic Noncoding RNA00265 Enhances Cell Viability and Metastasis via Targeting miR-485-5p/USP22 Axis in Osteosarcoma
    Chen, Ting
    Liu, Jinxin
    Zhang, He
    Li, Jiatong
    Shang, Guanning
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [10] Chen W, 2022, FRONT ONCOL, DOI DOI 10.3389/FONC.2022.1042928